1-13 of 13
S. Thompson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma

Damian J. Green, MD, Margot Pont, PhD, Blythe Duke Sather, PhD, Andrew J. Cowan, MD, Cameron J. Turtle, MBBS, PhD, Brian G. Till, MD, Anne M Nagengast, RN, Edward N. Libby, III, MD, Pamela S. Becker, MD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Brent Wood, MD PhD, Michelle Blake, PhD, Melissa Works, PhD, Bruce S Thompson, PhD, Ted Gooley, PhD, Frederick R. Appelbaum, MD, David G. Maloney, MD PhD, Stanley R. Riddell, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1011.
https://doi.org/10.1182/blood-2018-99-117729
Published: 2018
Journal Articles

A Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma

Ian W. Flinn, MD PhD, Thomas J. Ervin, MD, Ralph V. Boccia, MD, Douglas B. Flora, MD, J. Daniel Cuevas, MD, Dana S. Thompson, MD, Dianna L. Shipley, MD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2015) 126 (23): 1492.
https://doi.org/10.1182/blood.V126.23.1492.1492
Published: 2015
Journal Articles

Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute

Ian W. Flinn, MD, PhD, Dana S. Thompson, MD, Ralph V. Boccia, MD, Gerald Miletello, MD, Andrew Lipman, MD, Douglas Flora, MD, Daniel Cuevas, MD, Steven W. Papish, MD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2012) 120 (21): 1624.
https://doi.org/10.1182/blood.V120.21.1624.1624
Published: 2012
Journal Articles

Fludarabine, Rituximab, and Lenalidomide in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): A Phase I/II Trial of the Sarah Cannon Research Institute

Ian W. Flinn, MD, PhD, R. Seth Cooper, MD, Dana S. Thompson, MD, Jamie K. Waselenko, MD, James Reeves, Jr., MD, Rudolph L. Wise, MD, John D. Hainsworth, MD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2012) 120 (21): 715.
https://doi.org/10.1182/blood.V120.21.715.715
Published: 2012
Journal Articles

Rituximab +/− Bevacizumab for Patients with Previously Treated Follicular Non-Hodgkins Lymphoma: A Randomized Phase II Trial of the Sarah Cannon Research Institute.

John D. Hainsworth, MD, Dana S. Thompson, MD, F. Anthony Greco, MD, Eric Raefsky, MD, Scott Lunin, MD, James Reeves, Jr., MD, Ian W. Flinn, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2749.
https://doi.org/10.1182/blood.V120.21.2749.2749
Published: 2012
Journal Articles

Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Ian W. Flinn, MD, PhD, Jesus G. Berdeja, MD, Jamie K. Waselenko, MD, R. Seth Cooper, MD, Jia Bi, MD, Kent Shih, MD, Habib H. Doss, MD, Natalie Dickson, MD, Dana S. Thompson, MD, Howard A. Burris, III, MD, John D. Hainsworth, MD
Journal: Blood
Blood (2010) 116 (21): 2461.
https://doi.org/10.1182/blood.V116.21.2461.2461
Published: 2010
Journal Articles

Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade

Wei Yu Lin, Qian Gong, Dhaya Seshasayee, Zhonghua Lin, Qinglin Ou, Shiming Ye, Eric Suto, Jean Shu, Wyne Pun Lee, Ching-Wei V. Lee, Germaine Fuh, Maya Leabman, Suhasini Iyer, Kathy Howell, Thomas Gelzleichter, Joseph Beyer, Dimitry Danilenko, Sherry Yeh, Laura E. DeForge, Allen Ebens, Jeffrey S. Thompson, Christine Ambrose, Mercedesz Balazs, Melissa A. Starovasnik, Flavius Martin
Journal: Blood
Blood (2007) 110 (12): 3959–3967.
https://doi.org/10.1182/blood-2007-04-088088
Published: 2007
Includes: Supplemental data
Journal Articles

Effect of Graft Engineering and Post-Transplantation Immunosuppression Regimen on Immunophenotypic Recovery in Recipients of Unrelated Donor Bone Marrow (T-Cell Depletion Trial) in a Multicenter Randomized Phase II-III Trial.

Lawrence S. Lamb, PhD, John E. Wagner, MD, Nancy A. Kernan, MD, Trudy N. Small, MD, Shelly L. Carter, PhD, John S. Thompson, MD, Gretchen A. Cloud, PhD, Sreelatha Meleth, PhD, Anand Kumar, MD, Carolyn A. Keever-Taylor, PhD
Journal: Blood
Blood (2007) 110 (11): 1067.
https://doi.org/10.1182/blood.V110.11.1067.1067
Published: 2007
Journal Articles

Improvements in Health-Related Quality of Life of Patients with DLBCL after Treatment with Yttrium-90 Ibritumomab Tiuxetan ( 90 y-Zevalin).

S. S. Thompson, S. Macran, J. Kalmus, F. Morschhauser
Journal: Blood
Blood (2005) 106 (11): 4794.
https://doi.org/10.1182/blood.V106.11.4794.4794
Published: 2005
Journal Articles

Cost-Effectiveness of 90 Y-Ibritumomab Tiuxetan ( 90 Y-Zevalin) Versus Rituximab Monotherapy in Patients with Relapsed Follicular Lymphoma.

S. Thompson, M. van Agthoven
Journal: Blood
Blood (2005) 106 (11): 2436.
https://doi.org/10.1182/blood.V106.11.2436.2436
Published: 2005
Journal Articles

The Effect of Acute Protein Deprivation upon Erythropoiesis in Rats

W. F. BETHARD, R. W. WISSLER, J. S. THOMPSON, M. A. SCHROEDER, M. J. ROBSON
Journal: Blood
Blood (1958) 13 (3): 216–225.
https://doi.org/10.1182/blood.V13.3.216.216
Published: 1958
Journal Articles

The Effects of Acute Protein Depletion on the Distribution of Radioiron in Rat Tissues

W. F. BETHARD, R. W. WISSLER, J. S. THOMPSON, M. A. SCHROEDER, M. J. ROBSON
Journal: Blood
Blood (1958) 13 (2): 146–155.
https://doi.org/10.1182/blood.V13.2.146.146
Published: 1958
Journal Articles

An In Vitro Study of Antileukemic Serum

JOHN S. THOMPSON
Journal: Blood
Blood (1955) 10 (12): 1228–1235.
https://doi.org/10.1182/blood.V10.12.1228.1228
Published: 1955